NEO212

08/19/2015 - "In vitro, NEO212 effectively triggered tumor cell death, and its potency was significantly greater than that of its individual components, TMZ or POH alone. "
02/28/2016 - "In vivo studies show that NEO212 significantly delays tumor growth of both proneural and mesenchymal tumor stem cell populations. "
08/01/2014 - "In vivo studies show that NEO212 reduces intracranial tumor growth and increases animal survival without significant toxicity. "
12/09/2022 - "NEO212 has revealed robust therapeutic activity in a variety of preclinical cancer models, including AML. "
01/01/2020 - "Based on gas chromatography/mass spectrometry and high-performance liquid chromatography analyses, we determined that NEO212 had greater tumor cell uptake than TMZ. "

01/01/2018 - "These studies indicate that NEO212, in addition to cytotoxicity, can effectively reduce migration and invasion in GSCs, thus exhibiting significant clinical value in the reduction of invasion and malignant glioma progression. "
05/01/2018 - "NEO212: sub-cytotoxic doses capable of inhibiting glioma stem cell invasion."
01/01/2018 - "NEO212 Inhibits Migration and Invasion of Glioma Stem Cells."
02/28/2016 - "A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells."
01/01/2018 - "Furthermore, in an in vivo orthotopic glioma model, NEO212 decreases tumor progression by reducing invasion of GSCs, thereby increasing survival time of mice. "

06/07/2019 - "In the current study, we intend to illuminate the potential anticancer property and the underly mechanisms of NEO212 in ovarian cancer cells. "
06/07/2019 - "NEO212 inhibited TFEB translocation, and impaired the lysosomal function, implying NEO212 might avoid from autophagy mediated chemo-resistance, thus proposing NEO212 as a potential therapeutic candidate for ovarian cancer."
06/07/2019 - "NEO212 induces mitochondrial apoptosis and impairs autophagy flux in ovarian cancer."
06/07/2019 - "NEO212 has the potential anticancer property in ovarian cancer cells, as evidence from cell proliferation inhibition, G2/M arrest, DNA damage, xenograft, mitochondrial dysfunction and apoptosis. "

12/09/2022 - "In parallel toxicity studies with rats, a 5-day cycle of 200 mg/kg NEO212 was well tolerated by these animals, whereas animals that were given 200 mg/kg TMZ all died due to severe leukopenia. "

12/09/2022 - "NEO212, a Perillyl Alcohol-Temozolomide Conjugate, Triggers Macrophage Differentiation of Acute Myeloid Leukemia Cells and Blocks Their Tumorigenicity."
07/06/2021 - "Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia."